Endothelial progenitors encapsulated in bioartificial niches are insulated from systemic cytotoxicity and are angiogenesis competent.
Intrinsic stem cells (SC) participate in tissue remodeling and regeneration in various diseases and following toxic insults. Failure of tissue regeneration is in part attributed to lack of SC protection from toxic stress of noxious stimuli, thus prompting intense research efforts to develop strategies for SC protection and functional preservation for in vivo delivery. One strategy is creation of artificial SC niches in an attempt to mimic the requirements of endogenous SC niches by generating scaffolds with properties of extracellular matrix. Here, we investigated the use of hyaluronic acid (HA) hydrogels as an artificial SC niche and examined regenerative capabilities of encapsulated embryonic endothelial progenitor cells (eEPC) in three different in vivo models. Hydrogel-encapsulated eEPC demonstrated improved resistance to toxic insult (adriamycin) in vitro, thus prompting in vivo studies. Implantation of HA hydrogels containing eEPC to mice with adriamycin nephropathy or renal ischemia resulted in eEPC mobilization to injured kidneys (and to a lesser extent to the spleen) and improvement of renal function, which was equal or superior to adoptively transferred EPC by intravenous infusion. In mice with hindlimb ischemia, EPC encapsulated in HA hydrogels dramatically accelerated the recovery of collateral circulation with the efficacy superior to intravenous infusion of EPC. In conclusion, HA hydrogels protect eEPC against adriamycin cytotoxicity and implantation of eEPC encapsulated in HA hydrogels supports renal regeneration in ischemic and cytotoxic (adriamycin) nephropathy and neovascularization of ischemic hindlimb, thus establishing their functional competence and superior capabilities to deliver stem cells stored in and released from this bioartificial niche.
Ratliff
B B
BB
Department of Medicine, New York Medical College, Valhalla, New York 10595, USA.
Ghaly
T
T
Brudnicki
P
P
Yasuda
K
K
Rajdev
M
M
Bank
M
M
Mares
J
J
Hatzopoulos
A K
AK
Goligorsky
M S
MS
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity; D002460:Cell Line; D002465:Cell Movement; D049109:Cell Proliferation; D002470:Cell Survival; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000633:toxicity; D053595:Embryonic Stem Cells / Q000187:drug effects / Q000378:metabolism* / Q000637:transplantation; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism* / Q000637:transplantation; D005353:Fibronectins / Q000378:metabolism*; D006820:Hyaluronic Acid / Q000378:metabolism*; D020100:Hydrogels; D007511:Ischemia / Q000378:metabolism / Q000503:physiopathology; D007668:Kidney / Q000098:blood supply; D007674:Kidney Diseases / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D051379:Mice; D008807:Mice, Inbred BALB C; D018482:Muscle, Skeletal / Q000098:blood supply; D018919:Neovascularization, Physiologic; D012039:Regional Blood Flow; D055153:Stem Cell Niche; D033581:Stem Cell Transplantation; D013997:Time Factors; D023822:Tissue Engineering / Q000379:methods*; D054457:Tissue Scaffolds
D000903:Antibiotics, Antineoplastic; D005353:Fibronectins; D020100:Hydrogels; D004317:Doxorubicin; D006820:Hyaluronic Acid
Circ Res. 2002 Feb 22;90(3):284-8
11861416
N Engl J Med. 2003 Feb 13;348(7):593-600
12584367
Ther Adv Cardiovasc Dis. 2008 Jun;2(3):199-213
19124422
Stem Cells. 2007 Feb;25(2):447-54
17023515
J Intern Med. 1997 Jul;242(1):35-40
9260564
J Hypertens. 2005 Oct;23(10):1831-7
16148606
Blood Cells. 1978;4(1-2):7-25
747780
Am J Physiol Renal Physiol. 2005 Oct;289(4):F679-84
15928211
Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1246-52
15155385
Tissue Eng Part A. 2009 Jul;15(7):1591-9
19108679
Regen Med. 2009 Jul;4(4):561-78
19580405
Biomaterials. 2007 Feb;28(4):671-9
17049594
Circulation. 2002 Apr 2;105(13):1541-4
11927518
J Clin Endocrinol Metab. 2005 Sep;90(9):5329-32
15956081
J Am Coll Cardiol. 2005 May 3;45(9):1449-57
15862417
Science. 2006 Mar 31;311(5769):1880-5
16574858
Cell. 2008 Feb 22;132(4):598-611
18295578
Development. 2007 Jun;134(11):2001-6
17507401
Science. 1997 Feb 14;275(5302):964-7
9020076
Biomaterials. 2007 Feb;28(5):836-43
17034846
Circ Res. 2006 Jul 7;99(1):42-52
16763167
Circ Res. 2001 Jul 6;89(1):E1-7
11440984
N Engl J Med. 2005 Sep 8;353(10):999-1007
16148285
J Cell Physiol. 2006 May;207(2):331-9
16331674
Am J Physiol Renal Physiol. 2006 Jul;291(1):F176-85
16478972
Immunopharmacology. 2000 Feb;46(2):103-12
10647869
Prog Cardiovasc Dis. 2007 May-Jun;49(6):421-9
17498522
Circulation. 2004 Nov 23;110(21):3367-71
15520324
Diabetes. 2004 Jan;53(1):195-9
14693715
Regen Med. 2006 Jul;1(4):447-55
17465837
FASEB J. 2010 Jan;24(1):22-31
19726759
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11298-303
17581871
Arch Intern Med. 1977 Mar;137(3):385-8
843156
Circulation. 2002 Nov 26;106(22):2781-6
12451003
Development. 1998 Apr;125(8):1457-68
9502726
J Am Soc Nephrol. 2005 Oct;16(10):3110-20
16107582
Pharmacol Rev. 2006 Jun;58(2):244-58
16714487
J Biomed Mater Res A. 2006 Oct;79(1):1-5
16741988
Am J Pathol. 2010 Apr;176(4):1685-95
20167859
Circulation. 2003 Jul 29;108(4):457-63
12860902
Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):698-703
15662022
Exp Hematol. 2003 Feb;31(2):159-67
12591281